Robert Thomson - Artivion Vice Development
| AORT Stock | USD 24.43 0.23 0.95% |
Executive
Robert Thomson is Vice Development of Artivion
| Age | 55 |
| Phone | (770) 419-3355 |
| Web | https://artivion.com |
Robert Thomson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Thomson against Artivion stock is an integral part of due diligence when investing in Artivion. Robert Thomson insider activity provides valuable insight into whether Artivion is net buyers or sellers over its current business cycle. Note, Artivion insiders must abide by specific rules, including filing SEC forms every time they buy or sell Artivion'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Thomson over a year ago Acquisition by Robert Thomson of 126 shares of News Corp subject to Rule 16b-3 |
Artivion Management Efficiency
The company has return on total asset (ROA) of 0.0221 % which means that it generated a profit of $0.0221 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0479) %, meaning that it created substantial loss on money invested by shareholders. Artivion's management efficiency ratios could be used to measure how well Artivion manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Craig Swandal | Axogen Inc | 64 | |
| David Lehman | Pulmonx Corp | 63 | |
| David JD | Pulmonx Corp | 64 | |
| Hollie Foust | CONMED | N/A | |
| Bradley Nagel | Electromed | 43 | |
| Ben Joseph | Anika Therapeutics | N/A | |
| Rosalyn dIncelli | Establishment Labs Holdings | N/A | |
| Irina Ridley | Neuropace | 38 | |
| Doris Quackenbush | Axogen Inc | N/A | |
| Gordon JD | SurModics | 61 | |
| Isabelle Billet | Axogen Inc | 62 | |
| Michael JD | Si Bone | 47 | |
| Lauren Cristina | Pulmonx Corp | N/A | |
| Diane Kaufman | Electromed | N/A | |
| Warren Machan | Avanos Medical | 59 | |
| Reay MD | Sight Sciences | N/A | |
| Amy Yanta | Electromed | N/A | |
| Michael CPA | Anika Therapeutics | 51 | |
| Sarah Oliker | CONMED | 43 | |
| Jens Kemp | Axogen Inc | N/A | |
| Andrew Senn | Integer Holdings Corp | 43 | |
Management Performance
| Return On Equity | -0.0479 | ||||
| Return On Asset | 0.0221 |
Artivion Leadership Team
Elected by the shareholders, the Artivion's board of directors comprises two types of representatives: Artivion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Artivion. The board's role is to monitor Artivion's management team and ensure that shareholders' interests are well served. Artivion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Artivion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Bevevino, Independent Director | ||
| Jeffrey Burbank, Lead Independent Director | ||
| Jean Holloway, Senior Vice President Chief Compliance Officer, General Counsel, Secretary | ||
| Jon Salveson, Independent Director | ||
| Andrew Green, Vice President - Regulatory Affairs | ||
| Thomas Ackerman, Independent Director | ||
| Rochelle Maney, Vice President - Global Quality Assurance | ||
| Scott Capps, Vice President - Clinical Research | ||
| Marna Borgstrom, Independent Director | ||
| Matthew Getz, Vice President - Human Resources | ||
| James Bullock, Independent Director | ||
| Jean Esq, General VP | ||
| D Lee, Chief Financial Officer, Chief Operating Officer, Executive Vice President | ||
| CPA CPA, VP Officer | ||
| James Mackin, Chairman of the Board, President, Chief Executive Officer, Director | ||
| Anthony Semedo, Independent Director | ||
| Dennis Maier, Vice President - Operations | ||
| Joshua Wells, Sr Devel | ||
| Marshall Stanton, Senior Vice President Clinical Research and Chief Medical Officer | ||
| Marshall MD, Senior Officer | ||
| Robert Thomson, Vice Development | ||
| Amy CPA, VP Officer | ||
| Florian Tyrs, Vice Operations | ||
| Lance CPA, Executive CFO | ||
| F Barthold, Vice President - Research and Development | ||
| Amy Horton, Chief Accounting Officer, Vice President | ||
| John Davis, Senior Vice President - Global Sales and Marketing |
Artivion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Artivion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0479 | ||||
| Return On Asset | 0.0221 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 1.33 B | ||||
| Shares Outstanding | 42.05 M | ||||
| Shares Owned By Insiders | 5.91 % | ||||
| Shares Owned By Institutions | 92.24 % | ||||
| Number Of Shares Shorted | 3.83 M | ||||
| Price To Book | 3.71 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artivion Stock Analysis
When running Artivion's price analysis, check to measure Artivion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artivion is operating at the current time. Most of Artivion's value examination focuses on studying past and present price action to predict the probability of Artivion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artivion's price. Additionally, you may evaluate how the addition of Artivion to your portfolios can decrease your overall portfolio volatility.